Added to YB: 2025-10-01
Pitch date: 2025-08-13
PEPG [bullish]
PepGen Inc.
+341.74%
current return
Author Info
No bio for this author
Company Info
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
Market Cap
$324.7M
Pitch Price
$1.15
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.81
P/E
-1.71
EV/Sales
N/A
Sector
Biotechnology
Category
value
PepGen Inc. - $PEPG
PEPG: DM1 rare disease play at 50% net cash w/ data early 4Q25. RA Capital owns 33%+2 board seats, CEO ex-RA partner provides downside protection vs biotech zombie risk. 15mg/kg readout could show step-up from 29% missplicing correction at 10mg/kg. Avidity $6B mcap, Dyne $1.6B vs PEPG $300M despite potentially best-in-class profile.
Read full article (5 min)